Skip to main content
. 2021 Aug;9(16):1354. doi: 10.21037/atm-21-3861

Figure 1.

Figure 1

Chest CT images of an advanced NSCLC patient with EGFR exon 19 deletion. (A) At baseline. (B) Confirmed PR after 3 months of osimertinib. (C) Asymptomatic PD after 11 months of osimertinib. (D) Left lung lesion growth with left pleural effusion. (E) Immediate remission after the addition of cabozantinib. CT, computed tomography; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; PR, partial response; PD, progressive disease.